Aberrant activation of cyclin-dependent kinases (CDKs) is strongly correlated with tumor malignancy 10, and CDK4/6 inhibitors (CDK4/6is) have already been approved by the FDA for the treatment of breast cancer. This evidence concerns the gene CDK4 and neoplasm.